Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528

Author： Gadgeel Shirish   Lew Danika   Synold Timothy   LoRusso Patricia   Chung Vincent   Christensen Scott   Smith David   Kingsbury Laura   Hoering Antje   Kurzrock Razelle  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.72, Iss.5, 2013-11, pp. : 1089-1096

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

By Jerusalem Guy   Fasolo Angelica   Dieras Veronique   Cardoso Fatima   Bergh Jonas   Vittori Luc   Zhang Yufen   Massacesi Cristian   Sahmoud Tarek   Gianni Luca  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 447-455

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

By Wheler Jennifer   Janku Filip   Falchook Gerald   Jackson Tiffiny   Fu Siqing   Naing Aung   Tsimberidou Apostalia   Moulder Stacy   Hong David   Yang Hui   Piha-Paul Sarina   Atkins Johnique   Garcia-Manero Guillermo   Kurzrock Razelle  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 495-501

Springer Publishing Company

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer

By Cohen Steven   Gallo James   Lewis Nancy   Alpaugh R.   Gentner Louis   Rogatko André   Yeslow Gwen   Schol Jessie   Verhaeghe Tom   Zannikos Peter   Palmer Peter   Weiner Louis   Meropol Neal  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 6, 2004-06 ,pp. : 513-518

Springer Publishing Company

Access to resources Recommend Favorite

Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo

By Zhu Yuanxi  

Tumor Biology, Vol. 33, Iss. 5, 2012-10 ,pp. : 1349-1362

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study evaluating lapatinib in combination with nab -paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen

By Yardley Denise  

Breast Cancer Research and Treatment, Vol. 137, Iss. 2, 2013-01 ,pp. : 457-464

Springer Publishing Company

Access to resources Recommend Favorite